Progressive Radioiodine-Refractory Papillary Thyroid Carcinoma with Oncogenic NTRK Gene Fusion

A molecularly defined subset of advanced papillary thyroid carcinoma is characterised by disease that continues to progress despite radioiodine therapy and carries an oncogenic NTRK gene fusion. Confirming this molecular alteration changes the first-line treatment approach.

This protocol is indicated for progressive radioiodine-refractory (RAIR) papillary thyroid carcinoma in which tumour testing has identified an oncogenic NTRK gene fusion. In this specific population, the fusion represents a targetable driver, and guidelines recommend addressing it in the first line.

Management approach

First-line therapy in this setting is built around NTRK-targeted treatment — a class of agents that directly inhibit the oncogenic signalling driven by the NTRK fusion. The specific agent of choice and the full management algorithm are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/10507256251363120

In patients with progressive RAIR DTC harboring an oncogenic NTRK fusion, NTRK-targeted therapy is recommended in the first line.

View source ↗